A Phase 2 interventional study of Sugammadex and Placebo in Anesthesia, General, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the trial was to establish the dose-response relation of sugammadex (Org 25969) given as a reversal agent of rocuronium or vecuronium at reappearance of T2 (the amplitude of the first response of second twitch to train of four (TOF) stimulation, expressed as percentage of control first twitch, T1) during sevoflurane anesthesia for Caucasian participants.
For most surgical procedures a depth of neuromuscular block of 1-2 twitches after TOF-stimulation is sufficient to avoid unwanted muscular activity. At reappearance of T2, the anesthesiologist might decide to either give (another) maintenance dose of rocuronium or vecuronium when surgery continues, to await spontaneous recovery of neuromuscular block or to reverse the neuromuscular block. Sugammadex has been shown in previous trials to greatly reduce the time to full recovery when administered at reappearance of T2, both after rocuronium- and vecuronium induced neuromuscular blockade. The current trial P05971 was conducted in Europe and set up to establish the dose response relationship of sugammadex given during sevoflurane anesthesia at reappearance of T2 after rocuronium or vecuronium in Caucasian participants. In addition to recovery time, also pharmacokinetics and safety of sugammadex were to be evaluated.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
Drug: Placebo · Drug: Rocuronium
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Rocuronium
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Rocuronium
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Rocuronium
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Rocuronium
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
Drug: Placebo · Drug: Vecuronium
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Vecuronium
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Vecuronium
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Vecuronium
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
Drug: Sugammadex · Drug: Vecuronium
After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
Also known as: Org 25969
After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of Placebo IV was administered
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.
Time frame: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.
Time frame: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.
Time frame: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)
Caucasian participants who had a surgical procedure using a general anesthesia of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block were enrolled in this study.
| Milestone | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Treated | 10 | 10 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 9 |
| Completed | 10 | 10 | 9 | 9 | 10 | 8 | 10 | 10 | 8 | 9 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 2 | 1 |
| Withdrew: Not treated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 0 |
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.
| Minutes | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex |
|---|---|---|---|---|---|---|---|---|---|---|
| Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 | 96.30 ± 33.13 | 16.30 ± 20.60 | 4.62 ± 5.97 | 1.43 ± 0.50 | 1.50 ± 0.40 | 79.02 ± 25.97 | 35.50 ± 42.13 | 5.07 ± 2.38 | 3.42 ± 1.85 | 3.03 ± 2.18 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.
| Minutes | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex |
|---|---|---|---|---|---|---|---|---|---|---|
| Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7 | 65.67 ± 35.73 | 3.08 ± 2.25 | 2.08 ± 1.12 | 1.12 ± 0.40 | 1.02 ± 0.12 | 58.12 ± 21.90 | 12.57 ± 24.48 | 2.35 ± 0.48 | 2.00 ± 1.25 | 1.70 ± 0.55 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.
| Minutes | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex |
|---|---|---|---|---|---|---|---|---|---|---|
| Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8 | 75.85 ± 36.65 | 6.25 ± 9.12 | 2.62 ± 1.80 | 1.28 ± 0.42 | 1.15 ± 0.25 | 64.33 ± 21.72 | 25.65 ± 35.40 | 3.10 ± 0.88 | 5.83 ± 11.43 | 2.12 ± 0.80 |
Collected over Up to 7 days after sugammadex or placebo treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rocuronium + Placebo | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Rocuronium + 0.5 mg/kg Sugammadex | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Rocuronium + 1.0 mg/kg Sugammadex | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Rocuronium + 2.0 mg/kg Sugammadex | 1/10 (10%) | 1/10 (10%) | 10/10 (100%) |
| Rocuronium + 4.0 mg/kg Sugammadex | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Vecuronium + Placebo | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Vecuronium + 0.5 mg/kg Sugammadex | 0/10 (0%) | 2/10 (20%) | 10/10 (100%) |
| Vecuronium + 1.0 mg/kg Sugammadex | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Vecuronium + 2.0 mg/kg Sugammadex | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Vecuronium + 4.0 mg/kg Sugammadex | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex |
|---|---|---|---|---|---|---|---|---|---|---|
| Large intestine perforationGastrointestinal disorders | 0/10 | 0/10 | 0/9 | 0/10 | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 |
| Bladder tamponadeRenal and urinary disorders | 0/10 | 0/10 | 0/9 | 0/10 | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 |
| Urinary bladder haemorrhageRenal and urinary disorders | 0/10 | 0/10 | 0/9 | 0/10 | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/10 | 0/10 | 0/9 | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 0/9 |
| Event | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex |
|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/10 | 5/10 | 3/9 | 6/10 | 4/10 | 3/10 | 4/10 | 1/10 | 2/10 | 4/9 |
| Procedural painInjury, poisoning and procedural complications | 4/10 | 5/10 | 3/9 | 6/10 | 6/10 | 4/10 | 2/10 | 3/10 | 4/10 | 3/9 |
| VomitingGastrointestinal disorders | 2/10 | 4/10 | 1/9 | 2/10 | 1/10 | 1/10 | 3/10 | 0/10 | 0/10 | 4/9 |
| ConstipationGastrointestinal disorders | 1/10 | 3/10 | 0/9 | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 | 1/10 | 0/9 |
| HeadacheNervous system disorders | 0/10 | 0/10 | 0/9 | 3/10 | 2/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/9 |
| VertigoEar and labyrinth disorders | 1/10 | 0/10 | 2/9 | 0/10 | 0/10 | 0/10 | 2/10 | 0/10 | 0/10 | 0/9 |
| Abdominal painGastrointestinal disorders | 0/10 | 1/10 | 1/9 | 2/10 | 0/10 | 0/10 | 2/10 | 0/10 | 1/10 | 0/9 |
| Post procedural nauseaInjury, poisoning and procedural complications | 1/10 | 0/10 | 0/9 | 0/10 | 0/10 | 2/10 | 0/10 | 1/10 | 0/10 | 0/9 |
| Post procedural vomitingInjury, poisoning and procedural complications | 0/10 | 0/10 | 0/9 | 0/10 | 0/10 | 1/10 | 0/10 | 2/10 | 0/10 | 0/9 |
| Procedural hypotensionInjury, poisoning and procedural complications | 1/10 | 0/10 | 0/9 | 1/10 | 2/10 | 0/10 | 0/10 | 0/10 | 1/10 | 0/9 |
All Participants As Treated
| Age, Continuous(Years) | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 50 ± 7 | 52 ± 7 | 50 ± 9 | 49 ± 8 | 49 ± 13 | 48 ± 10 | 47 ± 9 | 46 ± 9 | 45 ± 10 | 47 ± 10 | 48 ± 9 |
| Sex: Female, Male(Participants) | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 8 | 7 | 5 | 6 | 8 | 7 | 7 | 7 | 7 | 70 |
| Male | 2 | 2 | 2 | 5 | 4 | 2 | 3 | 3 | 3 | 2 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Rocuronium + Placebo | Rocuronium + 0.5 mg/kg Sugammadex | Rocuronium + 1.0 mg/kg Sugammadex | Rocuronium + 2.0 mg/kg Sugammadex | Rocuronium + 4.0 mg/kg Sugammadex | Vecuronium + Placebo | Vecuronium + 0.5 mg/kg Sugammadex | Vecuronium + 1.0 mg/kg Sugammadex | Vecuronium + 2.0 mg/kg Sugammadex | Vecuronium + 4.0 mg/kg Sugammadex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 10 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 98 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
Ran from Sep 2005 to primary completion in Aug 2006, 11 months.
Results were first posted in Feb 2019, 12 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sugammadex · Rocuronium · Vecuronium